Potential for enhanced therapeutic activity of biological cancer therapies with doxycycline combination

Gene Therapy

Volumn 20, Issue 7, 2013, Pages 770-778

  Tang, H ^a,b   Sampath, P ^a   Yan, X ^b   Thorne, S H ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b KUNMING UNIVERSITY OF SCIENCE AND TECHNOLOGY   (China)

Author keywords

Doxycycline; Immunotherapy; MICA; NKG2D; Oncolytic virus

Indexed keywords

DOXYCYCLINE; MATRIX METALLOPROTEINASE; NATURAL KILLER CELL RECEPTOR NKG2D; ONCOLYTIC VIRUS; PROTEIN; PROTEIN MICA; PROTEIN MICB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER THERAPY; CELL SURFACE; CONTROLLED STUDY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL LINE; VACCINIA VIRUS; VIRUS REPLICATION;

CELL LINE, TUMOR; COMBINED MODALITY THERAPY; CYTOTOXICITY, IMMUNOLOGIC; DOXYCYCLINE; GENE EXPRESSION REGULATION, NEOPLASTIC; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOTHERAPY, ADOPTIVE; NEOPLASMS; NK CELL LECTIN-LIKE RECEPTOR SUBFAMILY K; ONCOLYTIC VIROTHERAPY; TRANSLATIONAL MEDICAL RESEARCH; VACCINIA VIRUS;

EID: 84880203628     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2012.96     Document Type: Article

References (38)

1. Turcotte S, Rosenberg SA. Immunotherapy for metastatic solid cancers. Adv Surg 2011; 45: 341-360.
2. Rosenberg SA, Yang JC, Sherry RM, Kammula US, Hughes MS, Phan GQ et al. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy. Clinical Cancer Research: an Official Journal of the American Association for Cancer Research 2011; 17: 4550-4557.
3. Robbins PF, Morgan RA, Feldman SA, Yang JC, Sherry RM, Dudley ME et al. Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011; 29: 917-924.
4. Geller MA, Miller JS. Use of allogeneic NK cells for cancer immunotherapy. Immunotherapy 2011; 3: 1445-1459.
5. Leemhuis T, Wells S, Scheffold C, Edinger M, Negrin RS. A phase I trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma. Biol Blood Marrow Transplant 2005; 11: 181-187.
6. Schmidt-Wolf IG, Lefterova P, Mehta BA, Fernandez LP, Huhn D, Blume KG et al. Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells. Exp Hematol 1993; 21: 1673-1679.
7. Lu PH, Negrin RS. A novel population of expanded human CD3CD56 cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency. J Immunol 1994; 153: 1687-1696.
8. Thorne SH, Negrin RS, Contag CH. Synergistic antitumor effects of immune cell-viral biotherapy. Science 2006; 311: 1780-1784.
9. Contag CH, Sikorski R, Negrin RS, Schmidt T, Fan AC, Bachireddy P et al. Definition of an enhanced immune cell therapy in mice that can target stem-like lymphoma cells. Cancer Res 2010; 70: 9837-9845.
10. Guo ZS, Thorne SH, Bartlett DL. Oncolytic virotherapy: molecular targets in tumorselective replication and carrier cell-mediated delivery of oncolytic viruses. Biochim Biophys Acta 2008; 1785: 217-231.
11. Kirn DH, Wang Y, Le Boeuf F, Bell J, Thorne SH. Targeting of interferon-beta to produce a specific, multi-mechanistic oncolytic vaccinia virus. PLoS Med 2007; 4: e353.
12. Thorne SH, Hwang TH, O'Gorman WE, Bartlett DL, Sei S, Kanji F et al. Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963. J Clin Invest 2007; 117: 3350-3358.
13. Park BH, Hwang T, Liu TC, Sze DY, Kim JS, Kwon HC et al. Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial. Lancet Oncol 2008; 9: 533-542.
14. Kirn DH, Thorne SH. Targeted and armed oncolytic poxviruses: a novel multi-mechanistic therapeutic class for cancer. Nat Rev Cancer 2009; 9: 64-71.
15. Breitbach CJ, Burke J, Jonker D, Stephenson J, Haas AR, Chow LQ et al. Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans. Nature 2011; 477: 99-102.
16. Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB. A new approach to generating antitumor effectors for adoptive immunotherapy using human adherent lymphokine-activated killer cells. Cancer Res 1988; 48: 3461-3469.
17. Sasaki A, Melder RJ, Whiteside TL, Herberman RB, Jain RK. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst 1991; 83: 433-437.
18. Visonneau S, Cesano A, Porter DL, Luger SL, Schuchter L, Kamoun M et al. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer. Clin Cancer Res 2000; 6: 1744-1754.
19. Tonn T, Becker S, Esser R, Schwabe D, Seifried E. Cellular immunotherapy of malignancies using the clonal natural killer cell line NK-92. J Hematother Stem Cell Res 2001; 10: 535-544.
20. Bauer S, Groh V, Wu J, Steinle A, Phillips JH, Lanier LL et al. Activation of NK cells and T cells by NKG2D, a receptor for stress-inducible MICA. Science 1999; 285: 727-729.
21. Groh V, Wu J, Yee C, Spies T. Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature 2002; 419: 734-738.
22. Kaiser BK, Yim D, Chow IT, Gonzalez S, Dai Z, Mann HH et al. Disulphideisomerase- enabled shedding of tumour-associated NKG2D ligands. Nature 2007; 447: 482-486.
23. Long EO. Tumor cell recognition by natural killer cells. Semin Cancer Biol 2002; 12: 57-61.
24. Huang B, Sikorski R, Sampath P, Thorne SH. Modulation of NKG2D-ligand cell surface expression enhances immune cell therapy of cancer. J Immunother 2011; 34: 289-296.
25. Armeanu S, Bitzer M, Lauer UM, Venturelli S, Pathil A, Krusch M et al. Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate. Cancer Res 2005; 65: 6321-6329.
26. Skov S, Pedersen MT, Andresen L, Straten PT, Woetmann A, Odum N. Cancer cells become susceptible to natural killer cell killing after exposure to histone deacetylase inhibitors due to glycogen synthase kinase-3-dependent expression of MHC class I-related chain A and B. Cancer Res 2005; 65: 11136-11145.
27. Peterson JT. Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 2004; 9: 63-79.
28. Burns FR, Stack MS, Gray RD, Paterson CA. Inhibition of purified collagenase from alkali-burned rabbit corneas. Invest Ophthalmol Vis Sci 1989; 30: 1569-1575.
29. Griffin MO, Fricovsky E, Ceballos G, Villarreal F. Tetracyclines: a pleitropic family of compounds with promising therapeutic properties. Review of the literature. Am J Physiol Cell Physiol 2010; 299: C539-C548.
30. Mistry AR, O'Callaghan CA. Regulation of ligands for the activating receptor NKG2D. Immunology 2007; 121: 439-447.
31. Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005; 436: 1186-1190.
32. Kraus RL, Pasieczny R, Lariosa-Willingham K, Turner MS, Jiang A, Trauger JW. Antioxidant properties of minocycline: neuroprotection in an oxidative stress assay and direct radical-scavenging activity. J Neurochem 2005; 94: 819-827.
33. Yrjanheikki J, Keinanen R, Pellikka M, Hokfelt T, Koistinaho J. Tetracyclines inhibit microglial activation and are neuroprotective in global brain ischemia. Proc Nat Acad Sci USA 1998; 95: 15769-15774.
34. Bakkenist CJ, Kastan MB. DNA damage activates ATM through intermolecular autophosphorylation and dimer dissociation. Nature 2003; 421: 499-506.
35. McCart JA, Ward JM, Lee J, Hu Y, Alexander HR, Libutti SK et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001; 61: 8751-8757.
36. Traktman P, Liu K, DeMasi J, Rollins R, Jesty S, Unger B. Elucidating the essential role of the A14 phosphoprotein in vaccinia virus morphogenesis: construction and characterization of a tetracycline-inducible recombinant. J Virol 2000; 74: 3682-3695.
37. Hedengren-Olcott M, Hruby DE. Conditional expression of vaccinia virus genes in mammalian cell lines expressing the tetracycline repressor. J Virol Methods 2004; 120: 9-12.
38. Rutella S, Iudicone P, Bonanno G, Fioravanti D, Procoli A, Lavorino C et al. Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol. Cytotherapy 2012; 14: 841-850.